StockData
Clearmind Medicine Inc. logo

Clearmind Medicine Inc. (CMND) stock

CMNDNasdaqPharmaceutical PreparationsFiscal year ends October 31
Financials through Q3 FY2026, quarter ended Jul 31, 2026Score 5/30
$4.62−0.33 (-6.67%)

Close on Nov 12, 2026Market cap $730.31KP/E –Yield –

Earnings

Clearmind Medicine's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Clearmind Medicine's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Clearmind Medicine has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Clearmind Medicine puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Clearmind Medicine filed with the SEC as exhibits to Form 8-K or 6-K

  1. PRESS RELEASE TITLED: "CLEARMIND MEDICINE AMONG TOP BIOPHARMA COMPANIES INVITED TO JOIN WASHINGTON DC, PSYCHEDELIC SUMMIT"
    6-K
  2. PRESS RELEASE TITLED: "CLEARMIND SUCCESSFULLY COMPLETES PATIENT RECRUITMENT FOR THE FIRST ALCOHOL USE DISORDER COHORT OF ITS CMND-100 PHASE I/IIA CLINICAL TRIAL"
    6-K
  3. PRESS RELEASE TITLED: "CLEARMIND: CHARGING ROBOTICS LAUNCHES NEXT-GENERATION AUTOMATED EV-CHARGING TECHNOLOGY FOR ROBOTAXIS AND AUTONOMOUS FLEETS"
    6-K
  4. PRESS RELEASE TITLED: "CLEARMIND ANNOUNCES PATENT PUBLICATION IN JAPAN COVERING TREATMENT FOR NEUROLOGICAL MOVEMENT DISORDER"
    6-K
  5. PRESS RELEASE TITLED: "CLEARMIND ADVANCES DIALOGUE WITH U.S. FEDERAL GOVERNMENT ON PSYCHEDELIC THERAPIES, SUBMITTING RECOMMENDATIONS TO FDA"
    6-K
  6. PRESS RELEASE TITLED: CLEARMIND ENHANCES U.S. IP PRESENCE WITH PUBLICATION OF THREE PATENT APPLICATIONS COVERING LSD, KETAMINE AND IBOGAINE COMBINATIONS
    6-K
  7. PRESS RELEASE TITLED: "CLEARMIND MEDICINE DELIVERS BRIEFING TO FDA FOLLOWING INVITATION TO HISTORIC PSYCHEDELIC HEARING IN WASHINGTON, D.C."
    6-K
  8. PRESS RELEASE TITLED: "CLEARMIND ENROLLS FIRST PATIENTS WITH ALCOHOL USE DISORDER IN CMND-100 CLINICAL TRIAL"
    6-K
  9. Condensed Interim Consolidated Financial Statements
    6-K
  10. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JULY 31, 2026
    6-K
  11. PRESS RELEASE TITLED: "CLEARMIND MEDICINE RECEIVES YALE IRB APPROVAL, ENABLING PATIENT RECRUITMENT FOR PARTS B AND C OF CMND-100 PHASE I/II TRIAL, FOLLOWING POSITIVE SAFETY RESULTS"
    6-K
  12. Clearmind Medicine Signs Definitive Agreement
    6-K
  13. This Conversion Agreement (this “Agreement”) is entered
    6-K
  14. PRESS RELEASE TITLED: "CLEARMIND REACHES KEY MILESTONE: CMND-100 PHASE IIA UNDERWAY FOR ALCOHOL USE DISORDER TRIAL, ONE-THIRD OF PART C ENROLLED"
    6-K
  15. PRESS RELEASE TITLED: "CLEARMIND ADVANCES MDMA-N-ACYLETHANOLAMINES IP FOR THE TREATMENT OF PTSD AMID RISING U.S. FEDERAL SUPPORT FOR PSYCHEDELIC INNOVATION"
    6-K

See a number that looks wrong?